Welcome to our dedicated page for Cooper SEC filings (Ticker: COO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning CooperCompanies’ dual reports on vision care and women’s health can feel like navigating two industries at once. Whether you’re trying to separate Biofinity lens sales from Paragard IUD revenue or trace how supply-chain costs flow through gross margin, each SEC filing layers dense medical-device jargon on top of strict accounting rules. Investors researching “CooperCompanies SEC filings explained simply” often end up downloading dozens of PDFs without finding the one chart they need.
Stock Titan removes that friction. Our AI reads every new submission to EDGAR—10-K, 10-Q, 8-K, DEF 14A, even the niche S-8—then delivers plain-English highlights in seconds. Want the latest “CooperCompanies quarterly earnings report 10-Q filing”? You’ll get segment revenue, currency impacts, and lens volume trends summarized side-by-side. Tracking “CooperCompanies insider trading Form 4 transactions” for executives buying shares ahead of major launches? Real-time alerts display each trade minutes after it posts. The same engine flags material events, so “CooperCompanies 8-K material events explained” becomes a one-paragraph brief instead of a 30-page exhibit.
Dig deeper with interactive tools. Compare R&D spend across years straight from the “CooperCompanies annual report 10-K simplified.” Review “CooperCompanies proxy statement executive compensation” tables to see how performance goals tie to fertility segment margin. Use our timeline view to spot “CooperCompanies Form 4 insider transactions real-time” alongside dividend declarations, turning raw disclosures into actionable context. From “understanding CooperCompanies SEC documents with AI” to fast “CooperCompanies earnings report filing analysis,” every document is organized, summarized, and updated the moment Cooper hits ‘submit.’ No pop-ups, no jargon—just the data that matters.
Albert G. White III, President & CEO and Director of Cooper Companies (COO), reported an insider purchase of 10,000 shares at $68.39 on 09/05/2025, increasing his beneficial ownership to 226,151 shares. The Form 4 was filed individually and signed by an attorney-in-fact on behalf of Mr. White.
Gerard H. Warner III, President of CooperVision and an officer of Cooper Companies (COO), acquired 1,450 shares of Company common stock on 09/05/2025 at $69.23 per share. After the purchase he beneficially owned 18,319 shares. The Form 4 was submitted by a single reporting person and signed by an attorney-in-fact on behalf of Mr. Warner.
Daniel G. McBride, EVP & Chief Operating Officer of The Cooper Companies (COO), reported an open-market purchase of company stock. The Form 4 discloses a purchase of 3,000 shares of Common Stock at a price of $65.04 per share, recorded as a purchase transaction. After this transaction, Mr. McBride directly beneficially owns 63,120 shares and indirectly beneficially owns 94,496 shares through The McBride Family Trust. No derivative securities are reported on this form.
Brian G. Andrews, identified as EVP, CFO & Treasurer of Cooper Companies, Inc. (COO), reported transactions in the issuer's common stock dated 09/02/2025. The Form 4 shows a purchase of 1,525 shares at a weighted average price of $65.68 (individual trade prices ranged from $65.25 to $65.97). After the reported transactions, the reporting person beneficially owns 22,191 shares indirectly through the Andrews Family Trust, of which he and his spouse are co-trustees. The filing also records a disposition of 6,902 shares. Footnotes state that 8,293 previously directly held shares were transferred to the Andrews Family Trust on 02/18/2025 and that 288 shares were acquired under the issuer's ESPP earlier in 2025.
The Cooper Companies, Inc. reported third-quarter fiscal 2025 results showing continued activity across acquisitions, financing and operations. The company completed acquisitions including obp Surgical for $100.0 million and a fertility company for $33.5 million in 2024, and earlier acquired select Cook Medical assets for $300.0 million (present value $291.6 million). Consolidated gross margin was 65% for the quarter (66% prior-year quarter) driven lower primarily by inventory write-offs related to a product line exit.
Liquidity and capital: working capital was $1,127.7 million versus $928.7 million a year earlier. Total outstanding debt carried an aggregate amount of $2.5 billion; $930.2 million was outstanding on the 2024 Revolving Credit Facility at a weighted-average interest rate of 5.43% and $1,500.0 million remained under the 2021 Term Loan. Share repurchases in the quarter totaled 0.7 million shares for $52.2 million, with $163.6 million remaining authorized. Management disclosed a material weakness in IT general controls impacting CooperSurgical and is implementing remediation steps.
FAQ
What is the current stock price of Cooper (COO)?
What is the market cap of Cooper (COO)?
